Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Earnings Results, Beats Expectations By $0.05 EPS

Perspective Therapeutics (NYSEAMERICAN:CATX) announced its quarterly earnings results on Monday. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.05, FiscalAI reports. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.09 million.

Perspective Therapeutics Price Performance

NYSEAMERICAN:CATX remained flat at $3.00 during trading hours on Monday. 911,985 shares of the company were exchanged, compared to its average volume of 2,355,088. The firm’s fifty day moving average is $3.11 and its 200-day moving average is $3.93. Perspective Therapeutics has a 12-month low of $1.96 and a 12-month high of $6.16.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CATX. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a research report on Friday, July 24th. Wedbush restated an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, May 5th. Eight investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $12.62.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CATX. Geode Capital Management LLC boosted its stake in shares of Perspective Therapeutics by 15.8% during the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after buying an additional 188,887 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Perspective Therapeutics by 118.4% in the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after purchasing an additional 405,612 shares during the period. Walleye Capital LLC increased its holdings in shares of Perspective Therapeutics by 375.8% in the second quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after purchasing an additional 148,013 shares during the period. Federated Hermes Inc. raised its stake in shares of Perspective Therapeutics by 44.4% during the second quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock worth $671,000 after purchasing an additional 60,019 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Perspective Therapeutics by 8.5% during the second quarter. Bank of America Corp DE now owns 327,500 shares of the company’s stock worth $1,127,000 after purchasing an additional 25,697 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.